Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma
Authors:
- Robert LimRLRobert Lim
- Michael BoyerMBMichael Boyer
- Ai-Bee OngAOAi-Bee Ong
- Seng-Weng WongSWSeng-Weng Wong
- Hwai-Loong KongHKHwai-Loong Kong
- Michael MillwardMMMichael Millward
- Stephen ClarkeSCStephen Clarke
- Boon-Cher GohBGBoon-Cher Goh
- 1 January 2007
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 46 (2) , 234-238
Abstract
Hepatocellular carcinoma (HCC) is a hypervascular tumour, which overexpresses vascular endothelial growth factor. Thalidomide is an antiangiogenic agent with activity in refractory multiple myeloma. The purpose of this multi-centre phase II study was to evaluate the efficacy and toxicity of thalidomide in patients with advanced HCC. From February 2000 to November 2001, 37 patients with histologically proven, bi-dimensionally measurable advanced, unresectable HCC were enrolled. The starting dose of Thalidomide was 100 mg per day and escalated weekly by 100 mg to a maximum dose of 800 mg/day according to individual patient tolerance. Radiological tumour response and treatment related toxicities were prospectively assessed. Thirty-seven patients were evaluable for toxicity and 24 patients were evaluable for response. The median Thalidomide dose was 400 mg/day. There was no complete response (CR). One patient had a radiological partial response (PR) (3%; 95% confidence interval [95% CI], 0% to 8%) and six (16%) patients had stable disease for more than 6 months. Somnolence and fatigue were the most common side effects, occurring in 84% and 73% of patients respectively. Thalidomide monotherapy is tolerable and associated with modest antitumour activity in advanced HCC.Keywords
This publication has 19 references indexed in Scilit:
- Thalidomide in the treatment of patients with hepatocellular carcinomaCancer, 2005
- Upregulation of endogenous angiogenesis inhibitors: A mechanism of action of metronomic chemotherapyCancer Biology & Therapy, 2004
- Phase II study of thalidomide in patients with unresectable hepatocellular carcinomaCancer, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Thalidomide as an anti‐cancer agentJournal of Cellular and Molecular Medicine, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Therapy of Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinomaCancer, 1993
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989